Accès ouvert · CC BY

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission

Article scientifique 2020 Sciences de la santé Anglais

Résumé

Efavirenz-based first-line regimens have been widely used for children ≥3 years of age starting antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We used logistic regression to examine the association between PMTCT exposure and viral failure (VF) defined as two consecutive viral loads (VL)>1000 copies/ml between 6-18 months on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI:0.56, 1.11).

Citer ce document

Nyakato, P., Davies, M., Technau, K., Fatti, G., Rabie, H., Tanser, F., Boulle, A., Wood, R., Eley, B., Sawry, S., Giddy, J., Sipambo, N., Kuhn, L., & Fairlie, L. (2020). Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS ONE. https://doi.org/10.1371/journal.pone.0233693

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 04/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 19

Téléchargements (hors robots) : 0

Méthode de comptage